Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago May 30, 2007
Rexahn Pharmaceuticals Receives FDA Approval to Initiate a Phase II Trial for Archexin in Patients with Renal Cell Carcinoma May 29, 2007
Rexahn Pharmaceuticals, Inc. to Present at The Robins Group Emerging Opportunities Investment Conference in New York City May 23, 2007
R&D Directions Magazine Names Rexahn's Leading Cancer Candidate, RX-0201 (Archexin) among ''100 Great Investigational Drugs'' Apr 5, 2007
Rexahn Awarded Maryland Industrial Partnerships Grant to Develop Targeted Nano-Polymer Cancer Drugs Mar 6, 2007
